4.5 Article

Treatment of Subsyndromal Depressive Symptoms in Middle-Age and Older Patients With Schizophrenia: Effect of Age on Response

Journal

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
Volume 18, Issue 9, Pages 853-857

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JGP.0b013e3181dba12f

Keywords

Schizophrenia; age differences; citalopram; depression; psychopathology; quality of life

Funding

  1. Cincinnati VA Medical Center
  2. University of Cincinnati College Of Medicine
  3. VISN 4
  4. VISN 22 MIRECC
  5. University of California, San Diego, CA.
  6. Center for Community-based Research in Older People with Psychoses
  7. Aspect Medical
  8. PamLab
  9. Forest
  10. Astra Zeneca
  11. Bristol Meyers Squibb
  12. Pfizer
  13. Johnson and Johnson
  14. Solvay
  15. Eli Lilly
  16. [MH6398]

Ask authors/readers for more resources

Objective: The authors hypothesized that age would moderate the response of patients with schizophrenia and subsyndromal depression (SSD) treated citalopram with depressive symptoms and other outcomes. Also, older patients would exhibit more side effects with citalopram. Methods: Participants of 40 years or older had schizophrenia or schizoaffective disorder with SSD. Patients randomly received flexible dosing of citalopram or placebo augmentation of their antipsychotic medication. Linear regression determined whether age had any moderating effect on depressive symptoms, global psychopathology, negative symptoms, mental functioning, and quality of life. Age-related side effects were examined. Results: There were no significant drug group by age interaction in depressive or psychotic symptoms, mental Short Form-12, or quality of life scores. Similarly, there were few age-related side effect differences. Conclusion: Symptoms in younger and older patients with schizophrenia and SSD treated with citalopram seem to respond similarly. Adverse events do not seem to differ with age. (Am J Geriatr Psychiatry 2010; 18:853-857)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available